Clinical trials
Myeloma clinical trials
Below are recruiting myeloma clinical trials, each written for real people, not researchers. We’re tracking 572 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT07585760RecruitingPhase 2
Study of CM336 and Isatuximab for new multiple myeloma with kidney problems
This trial tests a combination of two drugs, CM336 and Isatuximab, for people newly diagnosed with multiple myeloma that has caused kidney damage. The goal is to see if this treatment can help control the myeloma while also addressing the kidney issues.
TianjinAges 18–80 - NCT07377435RecruitingPhase 1
Vaccine after CAR-T therapy for multiple myeloma
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
Boston, MassachusettsAges 18 years+ - NCT07382739RecruitingPhase 2
Radiation and immunotherapy for advanced multiple myeloma
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
Houston, TexasAges Any age - NCT07446777Recruiting
Fasting and Mediterranean diet for multiple myeloma
This study tests whether a special diet—longer nightly fasting plus a Mediterranean eating pattern—can help people with multiple myeloma or its early stages. If you qualify, you will be randomly assigned to start the diet right away or join a waitlist group.
Miami, FloridaAges 18 years+ - NCT07479979RecruitingPhase 1/Phase 2
Study of selinexor with carfilzomib, isatuximab and dexamethasone for relapsed/refractory multiple myeloma
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
Madison, WisconsinAges 18 years+ - NCT07497165Recruiting
Epunamin plus DECP for returning or resistant multiple myeloma
This trial tests a combination of the study drug Epunamin with four chemotherapy drugs (dexamethasone, cisplatin, etoposide, and cyclophosphamide) for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Taiyuan, ShanxiAges 18–75 - NCT07541391RecruitingPhase 1
CAR T-cell therapy for relapsed kappa myeloma
This trial tests a new treatment called CAR T-cells (your own immune cells engineered in the lab) designed to fight kappa-restricted multiple myeloma that has come back or stopped responding to standard drugs. The goal is to see if this treatment can help patients whose cancer has progressed despite previous therapies.
Melbourne, VictoriaAges 18 years+ - NCT07609030Recruiting
Brain Training During CAR-T Cell Cancer Treatment
This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.
Columbus, OhioAges 18 years+ - NCT03815279Enrolling by invitationPhase 2
Trial for active or high-risk smoldering myeloma treatments
This Phase 2 study tests a treatment approach for adults with active multiple myeloma (MM) or a high/intermediate-risk “smoldering” MM that hasn’t been treated yet. It may help by trying to control the disease earlier or more effectively, depending on what the trial drug(s) do.
ReykjavikAges 18 years+ - NCT06630104Recruiting
Studying blood cell changes after CAR-T therapy for blood cancers
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
Scottsdale, ArizonaAges 18 years+ - NCT06375044RecruitingPhase 1
Study of SIM0500 for relapsed or refractory multiple myeloma
This trial tests a new medication, SIM0500, for people whose multiple myeloma has returned or stopped responding to other treatments. It aims to see if the drug is safe and effective for those who have tried all standard options.
Phoenix, ArizonaAges 18 years+ - NCT05976555RecruitingPhase 1
CAR T-cell therapy for relapsed myeloma after multiple treatments
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
Milwaukee, WisconsinAges 18–80 - NCT05632380RecruitingPhase 1/Phase 2
Stem cell transplant with CAR-T therapy for high-risk myeloma
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06066359RecruitingPhase 1/Phase 2
Cord blood NK cells for NY-ESO-1 positive myeloma
This trial tests a new treatment using cord blood immune cells (NK cells) that are specially designed to target a protein called NY-ESO-1 found on myeloma cells. It is for people with multiple myeloma that has come back or not responded to at least two previous treatments.
Houston, TexasAges 18–80 - NCT07393282RecruitingPhase 3
Comparing two treatments for high-risk smoldering multiple myeloma
This trial tests a new drug called linvoseltamab against an existing treatment, daratumumab, for people with a high-risk form of smoldering multiple myeloma. The goal is to see which one works better to delay or prevent the disease from becoming active multiple myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT06980480RecruitingPhase 3
Gammagard to prevent infections in multiple myeloma
This study tests if adding Gammagard (a type of antibody therapy) to your multiple myeloma treatment with Tecvayli can help prevent serious infections. You may qualify if you recently started Tecvayli and are still responding to it.
Mobile, AlabamaAges 18 years+ - NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+ - NCT06006741RecruitingPhase 1
CAR-T cell therapy for multiple myeloma patients
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
Shenzhen, GuangdongAges 18–80 - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT07296627Recruiting
Real-world immunotherapy for newly diagnosed multiple myeloma
This study looks at how well first-line immunotherapy works for people newly diagnosed with multiple myeloma in real-world clinical settings in China. The goal is to understand what treatments are used and how patients respond.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07222761RecruitingPhase 3
Comparing new treatments for relapsed multiple myeloma
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Atlanta, GeorgiaAges 18 years+ - NCT07087964Recruiting
PET scans to better understand multiple myeloma risk and disease
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
Antwerp, AntwerpenAges 18 years+
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloma?
- Yes. Clin2 currently lists 572 recruiting myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.